SABCS 2022 | Genetics and Inflammatory Markers for CIPN Study (GENIE) study

Daniel Rotroff, PhD, Lerner Research Institute, Cleveland, OH, provides an overview of the Genetics and Inflammatory Markers for CIPN Study (GENIE) study. The GENIE study was designed to develop biomarkers for predicting which patients with breast cancer receiving chemotherapy are at risk of developing peripheral chemotherapy induced peripheral neuropathy (CIPN). CIPN is one of the most common dose-limiting side effects seen among patients with early-stage breast cancer who received taxane-containing regimens. The trial is utilizing a multiomic approach to gain a comprehensive characterization of the patients molecular profile prior to receiving chemotherapy, as well as during and after treatment, to develop an algorithm to identify patients who are at risk of developing CIPN before or during taxane therapy. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.